0001193125-26-221625
SEC filingOperating loss improved 37% to $5.6M, and net loss improved 39% to $5.3M, driven by lower R&D costs from clinical wind-downs.
For the three months ended March 31, 2026, Equillium reported an operating loss of $5.6 million, a 36.8% improvement from $8.9 million in the prior-year period. Net loss improved 38.6% to $5.3 million from $8.7 million, and diluted earnings per share improved to $(0.06) from $(0.24). The improvement was primarily driven by lower research and development expenses as the company completed wind-down of certain clinical studies.
Net cash used in operating activities decreased to $4.3 million from $8.2 million in the prior-year period, reflecting disciplined expense management and lower clinical activity. Capital expenditures were minimal at $3,000, resulting in free cash flow of negative $4.3 million. The company has financed operations primarily through equity and debt securities, and in August 2025 expanded its treasury strategy to include digital currencies for diversification and liquidity.
Equillium expects research and development expenses to increase in future periods as it advances EQ504, its novel AhR modulator, into and through clinical development. The company plans to initiate a Phase 1 proof-of-mechanism study for EQ504 in mid-2026. Additionally, the company may resume development of EQ302 and expand into additional indications.
Equillium anticipates continued net losses for the foreseeable future and expects to need additional capital to fund research and development activities. The company's ability to execute its strategy depends on successful advancement of its pipeline and securing further financing.